Last reviewed · How we verify
Azstarys — Competitive Intelligence Brief
marketed
Metabolic
Small molecule
Live · refreshed every 30 min
Target snapshot
Azstarys (SERDEXMETHYLPHENIDATE) — Commcave Therapeutics Sa. Azstarys increases levels of dopamine and norepinephrine in the brain to help regulate attention and impulse control.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Azstarys TARGET | SERDEXMETHYLPHENIDATE | Commcave Therapeutics Sa | marketed | 2021-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Azstarys · 9079928 · US
- — Azstarys · 10584113 · US
- — Azstarys · 10759778 · US
- — Azstarys · 10584112 · US
- — Azstarys · 10954213 · US
- — Azstarys · 10858341 · US
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Azstarys — Competitive Intelligence Brief. https://druglandscape.com/ci/serdexmethylphenidate. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab